Top Markets
#1 Akedo Akedo +58.47%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.71%
#4 Cross Cross +45.85%
#5 Black Phoenix Black Phoenix +34.29%
#6 Velvet Velvet +30.75%
#7 OVERTAKE OVERTAKE +19.61%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.83%
#9 Cap Cap +15.18%
#10 QANplatform QANplatform +14.92%
Coin of the day
Akedo Akedo
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Aravive, Inc. Aravive, Inc.

Aravive, Inc.

ARAV
Rang in aandelen #38757
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston,... Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.
Aandeelprijs
$0.0401
Laatst gesynchroniseerd: 2024-02-07
Marktkapitalisatie
$818.60K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Aravive, Inc. (ARAV)

Categorie

Healthcare
EPS voor Aravive, Inc. (ARAV)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Aravive, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Aravive, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE